LTR Pharma (ASX:LTP) 3-1 Month Momentum %: 49.37% (As of Jul. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:LTP LTR Pharma Ltd ASX:LTP
7 GF Score
Price A$0.51
View Full Analysis

What is LTR Pharma 3-1 Month Momentum %?

LTR Pharma ASX:LTP -0.98% 7 3-1 Month Momentum % is 49.37% as of Jul. 20, 2026. GuruFocus rates ASX:LTP with a GF Score™ of 7/100. Among 1,386 Biotechnology companies, LTR Pharma ranks better than 92.14% on this metric.

3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-07-20), LTR Pharma's 3-1 Month Momentum % is 49.37%.

The industry rank for LTR Pharma's 3-1 Month Momentum % or its related term are showing as below:

ASX:LTP's 3-1 Month Momentum % is ranked better than
92.14% of 1386 companies
in the Biotechnology industry
Industry Median: -13.61 vs ASX:LTP: 49.37

LTR Pharma  (ASX:LTP) 3-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

LTR Pharma 3-1 Month Momentum % Related Terms

ASX:LTP vs VRTX, REGN, ALNY: 3-1 Month Momentum % Comparison

For the Biotechnology subindustry, LTR Pharma's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

LTR Pharma 3-1 Month Momentum % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, LTR Pharma's 3-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where LTR Pharma's 3-1 Month Momentum % falls into.


ASX:LTP
7GF Score
LTR Pharma Ltd ASX:LTP
3-1 Month Momentum % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

LTR Pharma  (ASX:LTP) 3-1 Month Momentum % Calculation

3-1 Month Momentum % is calculated as following:

3-1 Month Momentum %=( Price 1-month ago / Price 3-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 3-1 Month Momentum % →
What does a 3-1 Month Momentum % of 49.37% mean?
LTR Pharma (ASX:LTP) has a 3-1 Month Momentum % of 49.37% as of Jul. 20, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on LTR Pharma and its competitors. According to the industry distribution chart, LTR Pharma ranks #109 out of 1386 companies in the Biotechnology industry, placing it in the top 7.9%.
Is LTR Pharma's 3-1 Month Momentum % too high?
LTR Pharma's current 3-1 Month Momentum % is 49.37%. Based on the distribution chart, LTR Pharma ranks #109 out of 1386 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, LTR Pharma has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does LTR Pharma's 3-1 Month Momentum % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, LTR Pharma ranks #109 out of 1386 companies for 3-1 Month Momentum %. This places LTR Pharma in the top 8% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on LTR Pharma and its competitors. LTR Pharma's current 3-1 Month Momentum % is 49.37%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LTR Pharma stock overvalued right now?
LTR Pharma (ASX:LTP) has a current 3-1 Month Momentum % of 49.37%. The current 3-1 Month Momentum % is 49.37%. LTR Pharma's overall GF Score™ is 7/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For LTR Pharma (ASX:LTP), the current 3-1 Month Momentum % is 49.37% as of Jul. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

LTR Pharma Business Description

Address 9A/204 Alice Street, Brisbane, QLD, AUS, 4000
LTR Pharma Ltd is a clinical stage pharmaceutical company focused on holistically improving men's health, physically and mentally, through the commercialization of an intranasal spray treatment for Erectile Dysfunction. SPONTAN is a Vardenafil-based nasal delivery formulation designed to be a lower dose fast-acting administration that provides a rapid and high availability to a patient's bloodstream compared with the incumbent oral ED treatment products on the market.
7GF Score

Get the complete analysis for ASX:LTP

3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.51
Price